Singular Genomics Systems Stock Investor Sentiment
| OMIC Stock | USD 21.71 0.19 0.87% |
About 56% of all Singular Genomics' shareholders are looking to take a long position. The analysis of overall sentiment of trading Singular Genomics Systems stock suggests that some investors are interested at this time. The current market sentiment, together with Singular Genomics' historical and current headlines, can help investors time the market. In addition, many technical investors use Singular Genomics Systems stock news signals to limit their universe of possible portfolio assets.
Singular |
Singular Genomics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Singular Genomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Singular Genomics that are available to investors today. That information is available publicly through Singular media outlets and privately through word of mouth or via Singular internal channels. However, regardless of the origin, that massive amount of Singular data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Singular Genomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Singular Genomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Singular Genomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Singular Genomics alpha.
Singular Genomics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 312 shares by Andrew Spaventa of Singular Genomics subject to Rule 16b-3 | 09/13/2024 |
2 | Singular genomics CEO sells stock worth over 2,000 to cover taxes | 09/17/2024 |
3 | Acquisition by Tang Kevin of 32000 shares of Singular Genomics at 17.21 subject to Rule 16b-3 | 09/18/2024 |
4 | Acquisition by Jyotsna Ghai of 1666 shares of Singular Genomics subject to Rule 16b-3 | 10/02/2024 |
5 | Acquisition by Eli Glezer of 240000 shares of Singular Genomics subject to Rule 16b-3 | 10/03/2024 |
6 | Acquisition by Dalen Meeter of 15000 shares of Singular Genomics subject to Rule 16b-3 | 10/09/2024 |
7 | Acquisition by Ropp Sam of 100000 shares of Singular Genomics at 0.5355 subject to Rule 16b-3 | 10/17/2024 |
8 | Will Singular Genomics private investors stop to exit in December | 11/06/2024 |
9 | Acquisition by Jyotsna Ghai of 250 shares of Singular Genomics subject to Rule 16b-3 | 11/08/2024 |
10 | Disposition of 1212 shares by Andrew Spaventa of Singular Genomics subject to Rule 16b-3 | 11/12/2024 |
11 | Disposition of 250 shares by Eli Glezer of Singular Genomics subject to Rule 16b-3 | 11/26/2024 |
Complementary Tools for Singular Stock analysis
When running Singular Genomics' price analysis, check to measure Singular Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Singular Genomics is operating at the current time. Most of Singular Genomics' value examination focuses on studying past and present price action to predict the probability of Singular Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Singular Genomics' price. Additionally, you may evaluate how the addition of Singular Genomics to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |